• Tatiana O Kolesnikova
  • David S Galstyan
  • Konstantin A Demin
  • Mikhail A Barabanov
  • Alexander V Pestov
  • Murilo S de Abreu
  • Tatyana Strekalova
  • Allan V Kalueff

BACKGROUND: Cognitive deficits represent an urgent biomedical problem, and are commonly reduced by nootropic drugs. Animal models, including both rodents and zebrafish, offer a valuable tool for studying cognitive phenotypes and screening novel nootropics. Beta-alanine and its derivatives have recently been proposed to exert nootropic activity.

AIMS: This study aimed to characterize putative nootropic profile of a novel β-alanine analogue, 1,3-diaminopropane (MB-005), in adult zebrafish.

METHODS: Nootropic profile of MB-005 was assessed in adult zebrafish in the novel tank and conditioned place aversion (CPA) tests acutely, and in cued-learning plus-maze (PMT) tests chronically.

RESULTS/OUTCOMES: MB-005 did not alter zebrafish anxiety-like behavior or monoamine neurochemistry acutely, improved short-term memory in the CPA test, but impaired cognitive performance in both CPA and PMT tests chronically.

CONCLUSIONS/INTERPRETATION: This study reveals high sensitivity of zebrafish cognitive phenotypes to MB-005, suggesting it as a potential novel cognitive enhancer acutely, but raises concerns over its cognitive (and, possibly, other) side-effects chronically.

Original languageEnglish
Pages (from-to)892-902
Number of pages11
JournalJournal of Psychopharmacology
Volume36
Issue number7
Early online date17 Jun 2022
DOIs
StatePublished - Jul 2022

    Research areas

  • Nootropics, memory, piracetam, zebrafish, β-alanine, Behavior, Animal, Cues, beta-Alanine/pharmacology, Animals, Nootropic Agents/pharmacology, Zebrafish, Anxiety

    Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology

ID: 96511795